RxDoctor Payments Data

Meredith Donley, MD

Pulmonary Disease · Columbia, SCNPI 1639465727

Payments from drug & device makers

$394in general payments, 2019–2025

Across 16 payments — averaging $24.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$143
  • AstraZeneca$79
  • Verona Pharma, Inc.$72
  • Eisai Inc.$28
  • Insmed, Inc.$21
  • AbbVie$19
  • plus $32 from 2 others

What the payments were for

  • Food & beverage$37094%
  • Education$236%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$394 in reported general payments places this provider in the 15th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$88,481
Medicare patients
318
Services billed
1,361

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$347,234
Fasenra PenBenralizumab21$114,521
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$87,072
Dupixent PenDupilumab25$85,129
TezspireTezepelumab-Ekko21$81,922
Breztri AerosphereBudesonide/Glycopyr/Formoterol69$55,187
Spiriva RespimatTiotropium Bromide74$54,154
Stiolto RespimatTiotropium Br/Olodaterol Hcl56$49,606
SymbicortBudesonide/Formoterol Fumarate23$10,067
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$8,217
Advair HfaFluticasone Propion/Salmeterol11$3,851
Albuterol Sulfate HfaAlbuterol Sulfate186$3,810
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$2,787
Roflumilast15$1,096
Ventolin HfaAlbuterol Sulfate12$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$19$450,994157 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$79$147,176113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →